ZA961484B - Dna molecules preparation and use in gene therapy - Google Patents

Dna molecules preparation and use in gene therapy

Info

Publication number
ZA961484B
ZA961484B ZA961484A ZA961484A ZA961484B ZA 961484 B ZA961484 B ZA 961484B ZA 961484 A ZA961484 A ZA 961484A ZA 961484 A ZA961484 A ZA 961484A ZA 961484 B ZA961484 B ZA 961484B
Authority
ZA
South Africa
Prior art keywords
dna molecules
gene therapy
molecules preparation
preparation
genes
Prior art date
Application number
ZA961484A
Other languages
English (en)
Inventor
Beatrice Cameron
Joel Crouzet
Anne-Marie Darquet
Daniel Scherman
Pierre Wils
Original Assignee
Rhone Poulenc Rorer Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9476445&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA961484(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Rhone Poulenc Rorer Sa filed Critical Rhone Poulenc Rorer Sa
Publication of ZA961484B publication Critical patent/ZA961484B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6839—Triple helix formation or other higher order conformations in hybridisation assays
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/30—Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/55—Vector systems having a special element relevant for transcription from bacteria

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Plant Pathology (AREA)
  • Immunology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
ZA961484A 1995-02-23 1996-02-23 Dna molecules preparation and use in gene therapy ZA961484B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9502117A FR2731014B1 (fr) 1995-02-23 1995-02-23 Molecules d'adn, preparation et utilisation en therapie genique

Publications (1)

Publication Number Publication Date
ZA961484B true ZA961484B (en) 1996-08-28

Family

ID=9476445

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA961484A ZA961484B (en) 1995-02-23 1996-02-23 Dna molecules preparation and use in gene therapy

Country Status (19)

Country Link
US (3) US6143530A (fr)
EP (1) EP0815214B1 (fr)
JP (1) JPH11500618A (fr)
KR (1) KR19980702406A (fr)
AT (1) ATE366806T1 (fr)
AU (1) AU709111B2 (fr)
BR (1) BR9607273A (fr)
CA (1) CA2211427C (fr)
CZ (1) CZ266897A3 (fr)
DE (1) DE69637156T2 (fr)
FI (1) FI973467A0 (fr)
FR (1) FR2731014B1 (fr)
HU (1) HUP9801216A3 (fr)
IL (1) IL117214A0 (fr)
MX (1) MX9706109A (fr)
NO (1) NO973838L (fr)
SK (1) SK114397A3 (fr)
WO (1) WO1996026270A1 (fr)
ZA (1) ZA961484B (fr)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4428402A1 (de) * 1994-08-11 1996-02-15 Boehringer Mannheim Gmbh Gentherapeutisches Verfahren unter Verwendung von DNA-Vektoren ohne Selektionsmarker-Gen
FR2731014B1 (fr) * 1995-02-23 1997-03-28 Rhone Poulenc Rorer Sa Molecules d'adn, preparation et utilisation en therapie genique
US6825012B2 (en) * 1995-02-23 2004-11-30 Gencell S.A. DNA molecules, preparation and use in gene therapy
DE19648625A1 (de) 1996-11-13 1998-05-14 Soft Gene Gmbh Mikroprojektil für das Einbringen von Substanzen in Zellen durch ballistischen Transfer
EP1025217B1 (fr) 1997-10-24 2006-10-04 Invitrogen Corporation Clonage recombinatoire au moyen d'acides nucleiques possedant des sites de recombinaison
JP2002507429A (ja) * 1998-03-24 2002-03-12 アバンテイス・フアルマ・エス・アー 核酸導入ベクター、該ベクターを含有する組成物及びそれらの使用
FR2776669B1 (fr) * 1998-03-24 2001-06-15 Rhone Poulenc Rorer Sa Vecteurs de transfert d'acides nucleiques, compositions les contenant, et leurs utilisations
WO2000011155A1 (fr) * 1998-08-19 2000-03-02 The Board Of Trustees Of The Leland Stanford Junior University Procedes et compositions pour la modification de genomes
EP1165813A2 (fr) * 1999-03-24 2002-01-02 The Board Of Regents, The University Of Texas System Elements d'expression lineaires et circulaires
US6746870B1 (en) * 1999-07-23 2004-06-08 The Regents Of The University Of California DNA recombination in eukaryotic cells by the bacteriophage PHIC31 recombination system
DE19941186A1 (de) * 1999-08-30 2001-03-01 Peter Droege Sequenz-spezifische DNA-Rekombination in eukaryotischen Zellen
FR2803207B1 (fr) * 1999-12-30 2004-04-30 Aventis Pharma Sa Utilisation d'un vecteur comprenant un acide nucleique codant pour un facteur anti-angiogenique pour le traitement des neovascularisations corneennes
DK1246642T3 (da) * 1999-12-30 2006-01-09 Aventis Pharma Sa Anvendelse af en vektor, der omfatter en nukleinsyre, som koder for en antiangiogen faktor, til behandling af karnydannelser i hornhinden
JP4803945B2 (ja) * 2000-05-26 2011-10-26 アバンテイス・フアルマ・エス・アー 固定化オリゴヌクレオチドを使用する三重らせん形態の精製
BR0112633A (pt) * 2000-07-21 2003-09-16 Us Agriculture Método para substituir, translocar e empilhar dna em genomas eucarióticos
US7198924B2 (en) 2000-12-11 2007-04-03 Invitrogen Corporation Methods and compositions for synthesis of nucleic acid molecules using multiple recognition sites
JP4444564B2 (ja) * 2001-03-23 2010-03-31 サントリオン 三重螺旋相互作用によるターゲット二本鎖ｄｎａ配列の精製及び検出方法
FR2822476B1 (fr) * 2001-03-23 2004-04-02 Aventis Pharma Sa Procedes de purification et de detection de sequences cibles d'adn double brin par interaction triple helice
US7138267B1 (en) 2001-04-04 2006-11-21 Epicentre Technologies Corporation Methods and compositions for amplifying DNA clone copy number
GB0108968D0 (en) * 2001-04-10 2001-05-30 Imp College Innovations Ltd Methods
WO2002083889A2 (fr) * 2001-04-10 2002-10-24 Imperial College Innovations Limited Techniques
HUP0402659A3 (en) * 2001-05-30 2008-07-28 Glaxo Group Ltd Chromosome-based platforms
WO2003004088A2 (fr) 2001-07-05 2003-01-16 Aventis Pharma S.A. Procede d'injection d'un gene a etudier dans le coeur et le systeme vasculaire
US20030108524A1 (en) * 2001-10-18 2003-06-12 Melissa Diagana Vectors for expressing multiple transgenes
HUE025872T2 (en) 2002-06-18 2016-05-30 Eisai R&D Man Co Ltd Primary, cultured adipocytes for gene therapy
WO2004020605A2 (fr) 2002-08-29 2004-03-11 The Board Of Trustees Of The Leland Stanford Junior University Vecteurs circulaires d'acides nucleiques et procedes de preparation et d'utilisation de ceux-ci
US7314746B2 (en) 2002-09-13 2008-01-01 Valentis, Inc. Apparatus and method for preparative scale purification of nucleic acids
US20040166512A1 (en) * 2002-11-12 2004-08-26 Kahn Michael L. Method for cloning PCR products without restriction or ligation enzymes
AT412400B (de) 2003-05-08 2005-02-25 Mayrhofer Peter Mag Dr Minicircle-herstellung
WO2004111247A1 (fr) * 2003-06-10 2004-12-23 Mologen Ag Produit de synthese d'expression circulaire destine a des applications de therapie genique
WO2005054438A2 (fr) 2003-12-01 2005-06-16 Invitrogen Corporation Molecule d'acide nucleique contenant des sites de recombinaison et leurs procedes d'utilisation
US20060046294A1 (en) * 2004-08-26 2006-03-02 The United States Of America, As Represented By The Secretary Of Agriculture Site-specific recombination systems for use in eukaryotic cells
IL165365A0 (en) 2004-11-24 2006-01-15 Q Core Ltd Finger-type peristaltic pump
CN101437547A (zh) * 2005-01-20 2009-05-20 自然科技公司 用于遗传免疫的载体和方法
CA2608636C (fr) * 2005-05-17 2015-02-10 Frank Koentgen Systeme de clonage sequentiel
WO2007089871A2 (fr) * 2006-02-01 2007-08-09 The Johns Hopkins University Conjugue d'acide nucleique de polypeptides destine a l'immunoprophylaxie ou a l'immunotherapie des troubles neoplasiques ou infectieux
RU2010107199A (ru) * 2007-07-31 2011-09-10 Дзе Джонс Хопкинс Юниверсити (Us) Конъюгат полипептид-нуклеиновая кислота для иммунопрофилактики или иммунотерапии для неопластических или инфекционных нарушений
US8945885B2 (en) 2008-07-03 2015-02-03 The Board Of Trustees Of The Leland Stanford Junior University Minicircle DNA vector preparations and methods of making and using the same
US8236548B2 (en) 2008-07-03 2012-08-07 The Board Of Trustees Of The Leland Stanford Junior University Minicircle DNA vector preparations and methods of making and using the same
WO2011057825A1 (fr) 2009-11-16 2011-05-19 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Induction de l'expression génique chez des arthropodes
DE102009054265A1 (de) 2009-11-16 2011-05-26 Giese, Matthias, Dr. Orale Verabreichung von DNA an Insekten
DE102011118018B4 (de) 2011-10-25 2017-10-26 Plasmidfactory Gmbh & Co. Kg Minicircles mit Transpositionskassetten und ihre Verwendung zur Transformation von Zellen
GB201307075D0 (en) 2013-04-19 2013-05-29 Mayrhofer Peter Plasmid for minicircle production
DE102013220859B4 (de) 2013-10-15 2016-09-08 Plasmidfactory Gmbh & Co. Kg Minicircles mit viralen Expressionskassetten und ihre Verwendung zur Transformation von Zellen zur Erzeugung rekombinanter Viren oder viraler Genvektoren
KR20220128607A (ko) 2019-09-18 2022-09-21 인터갈락틱 테라퓨틱스, 인크. 합성 dna 벡터 및 사용 방법

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5028530A (en) * 1985-01-28 1991-07-02 Xoma Corporation AraB promoters and method of producing polypeptides, including cecropins, by microbiological techniques
EP0300422B1 (fr) * 1987-07-21 1992-12-02 The Du Pont Merck Pharmaceutical Company Méthode de préparation de vecteurs viraux recombinants stables et viables pour les cellules animales
FR2631634B1 (fr) * 1988-05-18 1991-06-14 Centre Nat Rech Scient Vecteurs de clonage et d'expression dans une souche d'actinomycete, procede de transformation de cette souche, souche d'actynomycete obtenue et preparation de proteines
US5227288A (en) * 1990-10-01 1993-07-13 Blattner Frederick R DNA sequencing vector with reversible insert
CA2131151A1 (fr) * 1992-03-24 1994-09-30 Kevin S. Johnson Methodes de production d'elements formant des paires specifiques de liaison
US5401632A (en) * 1992-07-16 1995-03-28 Wisconsin Alumni Research Foundation Triple helix purification and sequencing
AU5405994A (en) * 1992-10-16 1994-05-09 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Supercoiled minicircle dna as as a unitary promoter vector
DE19502584C2 (de) * 1994-01-28 1999-08-12 Medigene Ag Ges Fuer Molekular Verfahren zur Bestimmung der Aktivität eines regulatorischen Faktors sowie Verwendung dieses Verfahrens
FR2715940B1 (fr) * 1994-02-10 1996-04-26 Pasteur Merieux Serums Vacc Procédé de préparation d'une banque multicombinatoire de vecteurs d'expression de gènes d'anticorps, banque et systèmes d'expression d'anticorps "coliclonaux" obtenus.
DE4428402A1 (de) * 1994-08-11 1996-02-15 Boehringer Mannheim Gmbh Gentherapeutisches Verfahren unter Verwendung von DNA-Vektoren ohne Selektionsmarker-Gen
US6825012B2 (en) * 1995-02-23 2004-11-30 Gencell S.A. DNA molecules, preparation and use in gene therapy
FR2731014B1 (fr) * 1995-02-23 1997-03-28 Rhone Poulenc Rorer Sa Molecules d'adn, preparation et utilisation en therapie genique

Also Published As

Publication number Publication date
US6143530A (en) 2000-11-07
BR9607273A (pt) 1998-07-21
KR19980702406A (ko) 1998-07-15
ATE366806T1 (de) 2007-08-15
US6492164B1 (en) 2002-12-10
FI973467A7 (fi) 1997-08-22
CZ266897A3 (en) 1997-11-12
HUP9801216A2 (hu) 1998-08-28
US20030104444A1 (en) 2003-06-05
HUP9801216A3 (en) 2001-08-28
CA2211427C (fr) 2010-12-14
FR2731014B1 (fr) 1997-03-28
DE69637156T2 (de) 2008-02-07
FI973467L (fi) 1997-08-22
WO1996026270A1 (fr) 1996-08-29
NO973838L (no) 1997-10-13
JPH11500618A (ja) 1999-01-19
IL117214A0 (en) 1996-06-18
EP0815214B1 (fr) 2007-07-11
FR2731014A1 (fr) 1996-08-30
MX9706109A (es) 1997-11-29
DE69637156D1 (de) 2007-08-23
AU4882296A (en) 1996-09-11
SK114397A3 (en) 1998-02-04
FI973467A0 (fi) 1997-08-22
CA2211427A1 (fr) 1996-08-29
AU709111B2 (en) 1999-08-19
NO973838D0 (no) 1997-08-20
EP0815214A1 (fr) 1998-01-07

Similar Documents

Publication Publication Date Title
ZA961484B (en) Dna molecules preparation and use in gene therapy
HUP9900018A3 (en) Circular dna molecule with conditional origin of replication, method for preparing same and use thereof in gene therapy
HU9502702D0 (en) Dna constructs that contain influenza-virus genes and pharmaceutical preparations containing them
DE69636032D1 (de) Plasmid zur verabreichung von nukleine säuren und verwendungsverfahren
AU1606897A (en) Thymidine kinase variants, corresponding nucleic acid sequences and their use in gene therapy
AU2095599A (en) Human genes and gene expression products i
WO2001002568A3 (fr) Nouveaux genes humains et produits d'expression genique
AU4187499A (en) Human genes and gene expression products v
AU4053699A (en) Novel human genes and gene expression products
WO1998019167A3 (fr) Gene de classe i du complexe majeur d'histocompatibilite humain a stress cellulaire regule
AU3066992A (en) Cellular nucleic acid binding protein and uses thereof in regulating gene expression and in the treatment of aids
AP9901654A0 (en) Gene sequencer and methods.
AU9312198A (en) Genes amplified in tumours, antibodies against the proteins encoded thereby, andtheir use in diagnosis and treatment of cancer
AU4803997A (en) Polymorphisms and new genes in the region of the human hemochromatosis gene
DE69638166D1 (de) Integrin-gekoppelte kinase, ihre hemmstoffe und deren gebrauch für verfahren zur therapeutischen behandlung; gentherapie und bereitstellung von hemmstoffen, die als pseudosubstrate wirken
IL128872A0 (en) TNF-beta-like protein for treating prostate cancer and related nucleic acid molecules pharmaceutical compositions and methods
WO1995034669A3 (fr) Vecteurs retroviraux de therapie genique et procedes therapeutiques correspondants
AU3698297A (en) Compositions containing at least one nucleic acid and their applications in the biomedical field, particularly in gene therapy
AU4328399A (en) Nucleic acid-cobalamin complexes and their use in gene therapy
AU7665396A (en) Recombinant viruses containing mobile genetic elements and methods of use in gene therapy
AU6263999A (en) Human genes and gene expression products
GB9509461D0 (en) DNA molecules and constructs and their use in the treatment of mastitis
WO1998046747A3 (fr) Genes de la region de non-recombinaison du chromosome y
AU5554598A (en) Use of endothelin conjugates in therapy, new endothelin conjugates, substances containing them, and processes for producing them
Bowers Gene therapy recommendations